ArticleJournal of drug delivery2011
A liposomal formulation able to incorporate a high content of Paclitaxel and exert promising anticancer effect.
Article in Journal of drug delivery, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 91 citations in OpenAlex.
- Functional and therapeutic effects of Glabrescione B delivery by liposomes on Hedgehog-dependent tumors.Drug delivery and translational research · 2026Article
- A Library of Custom PEG-Lipids reveals a Double-PEG-Lipid with Drastically Enhanced Paclitaxel Solubility and Human Cancer Cell Cytotoxicity when used in Fluid Micellar Nanoparticles.bioRxiv : the preprint server for biology · 2024Article
- Preparation and molecular interaction of organic solvent-free piperine pro-liposome from soy lecithin.Heliyon · 2023Article
- Surface-engineered liposomes for dual-drug delivery targeting strategy against methicillin-resistantAsian journal of pharmaceutical sciences · 2022Article
- Paclitaxel loading in cationic liposome vectors is enhanced by replacement of oleoyl with linoleoyl tails with distinct lipid shapes.Scientific reports · 2021Article
- Liposomal formulation of HIF-1α inhibitor echinomycin eliminates established metastases of triple-negative breast cancer.Nanomedicine : nanotechnology, biology, and medicine · 2020Article
- Simple weak-acid derivatives of paclitaxel for remote loading into liposomes and improved therapeutic effects.RSC advances · 2020Article
- A Facile and Novel Approach to Manufacture Paclitaxel-Loaded Proliposome Tablet Formulations of Micro or Nano Vesicles for Nebulization.Pharmaceutical research · 2020Article
- Liposomal Nanostructures for Drug Delivery in Gastrointestinal Cancers.The Journal of pharmacology and experimental therapeutics · 2019Review
- Article
- Three-Dimensional Microphase Separation and Synergistic Permeability in Stacked Lipid-Polymer Hybrid Membranes.Chemistry of materials : a publication of the American Chemical Society · 2017Article
- Article
- Synthetic nanovaccines for immunotherapy.Journal of controlled release : official journal of the Controlled Release Society · 2017Review
- Practical Liposomal Formulation for Taxanes with Polyethoxylated Castor Oil and Ethanol with Complete Encapsulation Efficiency and High Loading Efficiency.Nanomaterials (Basel, Switzerland) · 2017Article
- Article
- Is an alternative drug delivery system needed for docetaxel? The role of controlling epimerization in formulations and beyond.Pharmaceutical research · 2013Article
- Improving oral bioavailability and pharmacokinetics of liposomal metformin by glycerolphosphate-chitosan microcomplexation.AAPS PharmSciTech · 2013Article
- A platelet-mimetic paradigm for metastasis-targeted nanomedicine platforms.Biomacromolecules · 2013Article
- Nanoparticle albumin bound Paclitaxel in the treatment of human cancer: nanodelivery reaches prime-time?Journal of drug delivery · 2013Article
- Application of liposomes in drug development--focus on gastroenterological targets.International journal of nanomedicine · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A liposome formulation for paclitaxel was developed in this study. The liposomes, composed of naturally unsaturated and hydrogenated phosphatidylcholines, with significant phase transition temperature difference, were prepared and characterized. The liposomes exhibited a high content of paclitaxel, which was incorporated within the segregated microdomains coexisting on phospholipid bilayer of liposomes. As much as 15% paclitaxel to phospholipid molar ratio were attained without precipitates observed during preparation. In addition, the liposomes remained stable in liquid form at 4°C for at least 6 months. The special composition of liposomal membrane which could reduce paclitaxel aggregation could account for such a capacity and stability. The cytotoxicity of prepared paclitaxel liposomes on the colon cancer C-26 cell culture was comparable to Taxol. Acute toxicity test revealed that LD(50) for intravenous bolus injection in mice exceeded by 40 mg/kg. In antitumor efficacy study, the prepared liposomal paclitaxel demonstrated the increase in the efficacy against human cancer in animal model. Taken together, the novel formulated liposomes can incorporate high content of paclitaxel, remaining stable for long-term storage. These animal data also demonstrate that the liposomal paclitaxel is promising for further clinical use.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.